Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Immunopathogenesis Versus Protection in Dengue Virus Infections.

Rothman AL, Medin CL, Friberg H, Currier JR.

Curr Trop Med Rep. 2014 Mar 1;1(1):13-20.

2.

Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.

Galula JU, Shen WF, Chuang ST, Chang GJ, Chao DY.

J Virol. 2014 Sep;88(18):10813-30. doi: 10.1128/JVI.00810-14. Epub 2014 Jul 9.

3.

Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection.

Weiskopf D, Angelo MA, Sidney J, Peters B, Shresta S, Sette A.

J Virol. 2014 Oct;88(19):11383-94. doi: 10.1128/JVI.01108-14. Epub 2014 Jul 23.

4.

Sculpting humoral immunity through dengue vaccination to enhance protective immunity.

Crill WD, Hughes HR, Trainor NB, Davis BS, Whitney MT, Chang GJ.

Front Immunol. 2012 Nov 8;3:334. doi: 10.3389/fimmu.2012.00334. eCollection 2012.

6.

The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.

Weiskopf D, Angelo MA, Bangs DJ, Sidney J, Paul S, Peters B, de Silva AD, Lindow JC, Diehl SA, Whitehead S, Durbin A, Kirkpatrick B, Sette A.

J Virol. 2015 Jan;89(1):120-8. doi: 10.1128/JVI.02129-14. Epub 2014 Oct 15.

7.

Dengue virus vaccine development.

Yauch LE, Shresta S.

Adv Virus Res. 2014;88:315-72. doi: 10.1016/B978-0-12-800098-4.00007-6. Review.

PMID:
24373316
8.

Influence of antibodies and T cells on dengue disease outcome: insights from interferon receptor-deficient mouse models.

Tang WW, Grewal R, Shresta S.

Curr Opin Virol. 2015 Aug;13:61-6. doi: 10.1016/j.coviro.2015.04.007. Epub 2015 May 23. Review.

PMID:
26001278
9.

CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice.

Zellweger RM, Tang WW, Eddy WE, King K, Sanchez MC, Shresta S.

J Virol. 2015 Jun;89(12):6494-505. doi: 10.1128/JVI.00036-15. Epub 2015 Apr 8.

10.

DHIM supporting immunologic investigations and the identification of immune correlates of protection.

Rothman AL.

J Infect Dis. 2014 Jun 15;209 Suppl 2:S61-5. doi: 10.1093/infdis/jiu111.

11.

Development of a recombinant, chimeric tetravalent dengue vaccine candidate.

Osorio JE, Partidos CD, Wallace D, Stinchcomb DT.

Vaccine. 2015 Dec 10;33(50):7112-20. doi: 10.1016/j.vaccine.2015.11.022. Epub 2015 Nov 14. Review.

PMID:
26585500
12.

Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity.

Messer WB, de Alwis R, Yount BL, Royal SR, Huynh JP, Smith SA, Crowe JE Jr, Doranz BJ, Kahle KM, Pfaff JM, White LJ, Sariol CA, de Silva AM, Baric RS.

Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1939-44. doi: 10.1073/pnas.1317350111. Epub 2014 Jan 2. Erratum in: Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):6115. Retraction in: Proc Natl Acad Sci U S A. 2015 May 19;112(20):E2738.

13.

Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera.

de Alwis R, Williams KL, Schmid MA, Lai CY, Patel B, Smith SA, Crowe JE, Wang WK, Harris E, de Silva AM.

PLoS Pathog. 2014 Oct 2;10(10):e1004386. doi: 10.1371/journal.ppat.1004386. eCollection 2014 Oct.

14.

Immune response to dengue virus and prospects for a vaccine.

Murphy BR, Whitehead SS.

Annu Rev Immunol. 2011;29:587-619. doi: 10.1146/annurev-immunol-031210-101315. Review.

PMID:
21219187
15.

Inhibition of dengue and chikungunya virus infections by RIG-I-mediated type I interferon-independent stimulation of the innate antiviral response.

Olagnier D, Scholte FE, Chiang C, Albulescu IC, Nichols C, He Z, Lin R, Snijder EJ, van Hemert MJ, Hiscott J.

J Virol. 2014 Apr;88(8):4180-94. doi: 10.1128/JVI.03114-13. Epub 2014 Jan 29.

16.

Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens.

Crill WD, Hughes HR, Delorey MJ, Chang GJ.

PLoS One. 2009;4(4):e4991. doi: 10.1371/journal.pone.0004991. Epub 2009 Apr 1.

17.

T-cell immunity to infection with dengue virus in humans.

Weiskopf D, Sette A.

Front Immunol. 2014 Mar 7;5:93. doi: 10.3389/fimmu.2014.00093. eCollection 2014. Review.

18.

Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization.

Messer WB, Yount B, Hacker KE, Donaldson EF, Huynh JP, de Silva AM, Baric RS.

PLoS Negl Trop Dis. 2012;6(2):e1486. doi: 10.1371/journal.pntd.0001486. Epub 2012 Feb 28.

19.

Understanding the contribution of cellular immunity to dengue disease pathogenesis.

Mathew A, Rothman AL.

Immunol Rev. 2008 Oct;225:300-13. doi: 10.1111/j.1600-065X.2008.00678.x. Review.

PMID:
18837790
20.

The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.

VanBlargan LA, Mukherjee S, Dowd KA, Durbin AP, Whitehead SS, Pierson TC.

PLoS Pathog. 2013;9(12):e1003761. doi: 10.1371/journal.ppat.1003761. Epub 2013 Dec 5.

Supplemental Content

Support Center